|Mr. Paul Peros||Exec. Chairman & CEO||577.68k||N/A||N/A|
|Mr. Jeffrey David Edwards||Founder, MD, Technical Director & Exec. Director||209k||N/A||N/A|
|Mr. Sergej Dolezil||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Matthew McIldowie||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Henko Vos C.A.||Company Sec.||N/A||N/A||N/A|
|Dr. Michael Roberts||Scientific Adviser||N/A||N/A||N/A|
Wellfully Limited, together with its subsidiaries, focuses on the development and commercialization of Dermaportation and ETP transdermal drug delivery technologies. It operates in two segments, Dermaportation Drug Delivery Technology and Devices. The company is also involved in the industrialization and supply-chain support for its existing product ranges; and sale and marketing of its own brands REDUIT and SWISSWELL, as well as third-party collaborations. It serves the pharmaceutical, cosmetic and skincare, and consumer healthcare sectors. The company was formerly known as OBJ Limited and changed its name to Wellfully Limited in September 2020. Wellfully Limited was incorporated in 1992 and is based in Leederville, Australia.
Wellfully Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.